Gregory Ginger, Executive Vice President of Human Resources at Biogen Inc. (BIIB), has demonstrated a consistent pattern of selling company shares over the past few years, as disclosed in SEC Form 4 filings. Ginger’s trading activity reveals a clear selling bias, with no recorded purchases of BIIB stock. Since January 2024, Ginger has executed multiple sales, totaling approximately $1.53 million in value. Notably, significant transactions include a sale of $336,287.80 on February 16, 2024, and another of $227,735.76 on February 6, 2026. These sales were often executed in clusters, such as the series of transactions on February 6, 2026, which included sales valued at $133,985.88 and $159,133.38 on the same day.
Ginger’s trading activity is exclusively tied to Biogen, with no recorded transactions involving other companies. The filings indicate that the majority of these sales were classified under transaction code "F," representing dispositions of securities through a broker or other intermediary. While the filings do not specify the reasons behind these transactions, the consistent pattern of selling suggests a focus on liquidating holdings rather than acquiring additional shares. This activity aligns with Ginger’s role as a senior executive, where periodic divestments may be part of broader financial planning or portfolio management strategies. The data underscores a clear trend of reducing equity exposure in Biogen over time.
AI-assisted summary